Tocilizumab for the treatment of COVID-19.
作者信息
Fernández-Ruiz Mario, López-Medrano Francisco, Aguado José María
机构信息
Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (Imas12), Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
出版信息
Expert Opin Biol Ther. 2021 Apr;21(4):431-434. doi: 10.1080/14712598.2021.1880563. Epub 2021 Jan 27.
Abstract
摘要
相似文献
1
Tocilizumab for the treatment of COVID-19.托珠单抗用于治疗新型冠状病毒肺炎。
Expert Opin Biol Ther. 2021 Apr;21(4):431-434. doi: 10.1080/14712598.2021.1880563. Epub 2021 Jan 27.
2
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
3
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.皮下注射托珠单抗治疗成人重症和危重症 COVID-19：一项前瞻性开放标签非对照多中心试验。
Int Immunopharmacol. 2020 Dec;89(Pt B):107102. doi: 10.1016/j.intimp.2020.107102. Epub 2020 Oct 13.
4
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
5
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.面向 ICU 收治的 COVID-19 患者的托珠单抗固定剂量：一项观察性群体药代动力学和描述性药效学研究的结果。
Clin Pharmacokinet. 2022 Feb;61(2):231-247. doi: 10.1007/s40262-021-01074-2. Epub 2021 Oct 11.
6
Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study.皮下注射托珠单抗治疗重症新型冠状病毒肺炎相关细胞因子释放综合征：一项观察性队列研究。
EClinicalMedicine. 2020 Jul 1;24:100410. doi: 10.1016/j.eclinm.2020.100410. eCollection 2020 Jul.
7
Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.地塞米松和托珠单抗治疗显著降低了 C 反应蛋白和降钙素原检测 COVID-19 患者继发细菌性感染的价值。
Crit Care. 2021 Aug 5;25(1):281. doi: 10.1186/s13054-021-03717-z.
8
Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.托珠单抗辅助治疗中重度 COVID-19 肺炎患者：一项观察性研究。
J Assoc Physicians India. 2022 Jan;70(1):11-12.
9
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
10
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 住院患者的疗效：系统评价和荟萃分析。
Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3.
引用本文的文献
1
Corticosteroids: A boon or bane for COVID-19 patients?皮质类固醇：对 COVID-19 患者是福还是祸？
Steroids. 2022 Dec;188:109102. doi: 10.1016/j.steroids.2022.109102. Epub 2022 Aug 24.
2
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.托珠单抗治疗新型冠状病毒肺炎：一项匹配的回顾性队列分析。
Med Clin (Engl Ed). 2022 Jun 24;158(12):608-612. doi: 10.1016/j.medcle.2021.06.025. Epub 2022 Jun 22.
3
Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study.托珠单抗治疗中重度 COVID-19 肺炎成人患者：一项单中心回顾性研究。
Int J Infect Dis. 2022 Apr;117:1-7. doi: 10.1016/j.ijid.2022.01.048. Epub 2022 Jan 27.
4
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.分析预测重症 COVID-19 患者对托珠单抗治疗临床应答的因素。
Int J Infect Dis. 2022 Apr;117:56-64. doi: 10.1016/j.ijid.2022.01.040. Epub 2022 Jan 23.
5
Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects.肝移植患者的2019冠状病毒病：临床与治疗方面
World J Hepatol. 2021 Oct 27;13(10):1299-1315. doi: 10.4254/wjh.v13.i10.1299.
6
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.托珠单抗治疗 SARS-CoV-2 肺炎：一项匹配的回顾性队列分析。
Med Clin (Barc). 2022 Jun 24;158(12):608-612. doi: 10.1016/j.medcli.2021.06.014. Epub 2021 Jun 18.
7
COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?2020 年西班牙实体器官移植受者中的 COVID-19：赶上浪潮？
Transplantation. 2021 Oct 1;105(10):2146-2155. doi: 10.1097/TP.0000000000003873.
本文引用的文献
1
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
2
Cytokine Storm.细胞因子风暴
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
3
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.托珠单抗治疗重症 COVID-19 患者的肺血管改善。
Immunol Lett. 2020 Dec;228:122-128. doi: 10.1016/j.imlet.2020.10.009. Epub 2020 Nov 5.
4
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
5
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
6
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
7
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.COVID-19 重症患者早期使用托珠单抗治疗与死亡率的关联。
JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252.
8
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高：快速系统评价、荟萃分析，并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
9
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).托珠单抗或皮质类固醇治疗伴有炎症过高状态的 COVID-19 患者：一项多中心队列研究（SAM-COVID-19）。
Clin Microbiol Infect. 2021 Feb;27(2):244-252. doi: 10.1016/j.cmi.2020.08.010. Epub 2020 Aug 27.
10
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者：一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
Zotero 插件